Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Area of Science:

• Pharmacology
• Hematology
• Clinical Trials

Background:

• Andexanet alfa is a modified factor Xa decoy protein designed to reverse anticoagulation.
• Factor Xa inhibitors are widely used but carry a risk of major bleeding.
• Effective reversal agents are crucial for managing bleeding complications.

Purpose of the Study:

• To evaluate the efficacy and safety of andexanet alfa in patients experiencing acute major bleeding while on factor Xa inhibitors.
• To assess the impact of andexanet alfa on anti-factor Xa activity and clinical hemostasis.

Main Methods:

• A multicenter, prospective, open-label, single-group study involving 67 patients with acute major bleeding.
• Patients received an initial bolus of andexanet alfa followed by a 2-hour infusion.
• Anti-factor Xa activity and clinical hemostatic efficacy were assessed over 12 hours, with 30-day follow-up.

Main Results:

• Andexanet alfa significantly reduced anti-factor Xa activity by 89-93% after bolus administration in patients on rivaroxaban or apixaban.
• Clinical hemostasis was adjudicated as excellent or good in 79% of the efficacy population (37/47 patients).
• Thrombotic events occurred in 18% of patients during the 30-day follow-up period.

Conclusions:

• Andexanet alfa effectively and rapidly reduces anti-factor Xa activity in patients with major bleeding associated with factor Xa inhibitors.
• The drug demonstrated effective hemostasis in a significant majority of patients.
• Further analysis is warranted, considering the observed thrombotic events.